Mutation: the changing of the structure of a gene, resulting in a variant form that may be transmitted to subsequent generations, caused by the alteration of single base units in DNA, or the deletion, insertion, or rearrangement of larger sections of genes or chromosomes.
Several SARS-CoV-2 variants are circulating globally. The most prominent variants of concern, including the B.1.1.7, B.1.351 and B1.1.28 lineages, not only carry a constellation of genetic m...
This presentation will focus on strategies for the design and validation of robust assays for the detection of SARS-CoV-2, including nucleic acid extraction, multiplexed qPCR assays, and int...
The COVID19 pandemic continues to be a major epidemiological challenge across the globe. Part of the challenge, often seen with viruses, is that the nucleic acid genome quickly mutates, prod...
Despite a continuous decline of corona virus cases, the broad rollout of multiple vaccines, and the start of a return to normalcy, concerns of SARS-CoV-2 outbreaks continue to linger on the...
G protein-coupled receptors (GPCRs) are among the most intensively studied drug targets, and account for about ~34% of all drugs approved by the FDA. Examples of drugs targeting GPCRs includ...
Date: February 24, 2021 Time: 7:00am (PST) Nucleotide variants can cause functional changes by altering protein–RNA binding in various ways that are not easy to predict. This can affec...
Date: January 26, 2021 Time: 9:00am (PST), 12:00pm (EST) Over the past years, CRISPR/Cas genome editing has quickly become the method of choice for genetic manipulation, owing to its ease-of...
This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
Date: October 28, 2020 Time: 7:00am (PDT), 10:00am (EDT) Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half o...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Several SARS-CoV-2 variants are circulating globally. The most prominent variants of concern, including the B.1.1.7, B.1.351 and B1.1.28 lineages, not only carry a constellation of genetic m...
This presentation will focus on strategies for the design and validation of robust assays for the detection of SARS-CoV-2, including nucleic acid extraction, multiplexed qPCR assays, and int...
The COVID19 pandemic continues to be a major epidemiological challenge across the globe. Part of the challenge, often seen with viruses, is that the nucleic acid genome quickly mutates, prod...
Despite a continuous decline of corona virus cases, the broad rollout of multiple vaccines, and the start of a return to normalcy, concerns of SARS-CoV-2 outbreaks continue to linger on the...
G protein-coupled receptors (GPCRs) are among the most intensively studied drug targets, and account for about ~34% of all drugs approved by the FDA. Examples of drugs targeting GPCRs includ...
Date: February 24, 2021 Time: 7:00am (PST) Nucleotide variants can cause functional changes by altering protein–RNA binding in various ways that are not easy to predict. This can affec...
Date: January 26, 2021 Time: 9:00am (PST), 12:00pm (EST) Over the past years, CRISPR/Cas genome editing has quickly become the method of choice for genetic manipulation, owing to its ease-of...
This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
Date: October 28, 2020 Time: 7:00am (PDT), 10:00am (EDT) Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half o...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
During the presentation, Dr. Hernandez-Losa will describe the experience in the Department of Pathology using NGS with S5-xl in different translational projects in solid tumors. Additionally...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in onc...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
Follow
